#United States #Los Angeles #Afaxys #Aspivix #carevix

Aspivix Partners with Afaxys GPO

In a significant move to enhance gynecological care in the United States, Aspivix, a company dedicated to pioneering gentle medical technologies, has announced its collaboration with Afaxys Group Purchasing Organization (GPO). This strategic partnership aims to make carevix®, a cutting-edge cervical stabilizer, available to all Afaxys members nationwide.

A New Era for Gynecological Procedures

The introduction of carevix® marks a groundbreaking alternative to the traditional tenaculum, often criticized for its invasive nature. Clinical studies reveal that this innovative suction-based tool significantly reduces both pain and bleeding during intrauterine device (IUD) placements. Patients experiencing IUD insertions using carevix® reported an astonishing 73% less pain and an 83% decrease in bleeding compared to the conventional methods.

Improving Patient Experience

With the growing emphasis on patient-centered care in gynecology, as underscored by the American College of Obstetricians and Gynecologists (ACOG), the partnership between Aspivix and Afaxys resonates with contemporary medical protocols advocating for a gentler approach to invasive procedures. ACOG's 2025 Clinical Consensus emphasizes the importance of counseling patients about anticipated pain and involving them in decision-making about their treatment options.

The accessibility of carevix® through Afaxys allows healthcare providers to incorporate this innovative device into their existing workflows seamlessly—aiming for enhanced patient comfort without disrupting standard procedures.

Data-Driven Insights and Community Impact

Backed by an impressive array of clinical data, carevix® has received approval from various health regulatory bodies, including the FDA, marking its credibility in modern healthcare. In a prospective study involving 1,123 IUD placements across 19 centers, the impact of carevix® on patient satisfaction was palpable, with approximately 94% of participants expressing their approval of the overall experience. Moreover, healthcare professionals highlighted the device’s ease of use and the low levels of discomfort reported by patients, making it an attractive addition to standard gynecological practices.

The partnership not only aims to enhance patient comfort during gynecological procedures but also seeks to support providers in delivering a comprehensive, evidence-based care model, ultimately benefiting public health initiatives across various communities.

The Commitment to Gentler Gynecological Care

Mathieu Horras, CEO of Aspivix, highlighted the significance of collaborating with Afaxys GPO, stating: "Joining forces with Afaxys GPO is an important milestone in our mission to make gentler gynecological care accessible to more women across the USA. Together, we aim to accelerate access to our innovation designed to improve the IUD experience and provide patients with the care they deserve.”

Aspivix's dedication to modernizing women's healthcare indicates a positive shift towards incorporating innovative, less painful solutions, empowering women to take control of their reproductive health.

Conclusion

As more healthcare providers explore the benefits of carevix®, the partnership with Afaxys GPO is poised to bring forth a new wave of advancements in patient-centered care for gynecological procedures across the U.S. With carevix®, the emphasis shifts towards empathy in medical practices—transforming not just procedures but overall experiences in women’s healthcare.

For Afaxys members interested in trying carevix®, samples are available along with comprehensive product support, ensuring that healthcare teams have the resources they need to enhance their patients' experiences—and ultimately, their health outcomes. For further details, visit Aspivix's website.